RBC Capital on 4D Molecular Therapeutics (FDMT): 'Story Remains On Track for Late-Stage Execution in wAMD and Pipeline Growth' Jan 7, 2026 10:22AM
4D Molecular Therapeutics (FDMT) PT Raised to $32 at RBC Capital Nov 11, 2025 08:39AM
4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q3 EPS Nov 10, 2025 05:01PM
Morgan Stanley Upgrades 4D Molecular Therapeutics (FDMT) to Equalweight Nov 7, 2025 04:28AM
4D Molecular Therapeutics (FDMT) PT Raised to $17 at Leerink Partners Oct 31, 2025 09:20AM


Oct 21, 2025 09:11AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Aug 11, 2025 11:34AM Goldman Sachs Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Aug 11, 2025 11:33AM 4D Molecular Therapeutics (FDMT) PT Lowered to $16 at Leerink Partners
Aug 11, 2025 10:54AM 4D Molecular Therapeutics, Inc. (FDMT) Misses Q2 EPS by 25c
Jul 2, 2025 04:07PM 4D Molecular Therapeutics (FDMT) Announces Accelerated 4D-150 Phase 3 Development in Wet AMD and Streamlined Organization to Drive Late-Stage Execution
May 8, 2025 07:30PM 4D Molecular Therapeutics, Inc. (FDMT) Reports In-Line Q1 EPS
May 1, 2025 08:01AM 4D Molecular Therapeutics Inc. (FDMT) Announces RMAT Designation Granted by FDA for 4D-150 for DME
Feb 10, 2025 02:30PM 4D Molecular Therapeutics (FDMT) PT Lowered to $40 at Jefferies
Feb 10, 2025 06:40AM H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Jan 13, 2025 06:20AM 4D Molecular Therapeutics (FDMT) PT Lowered to $27 at Leerink Partners
Jan 13, 2025 04:43AM BMO Capital Downgrades 4D Molecular Therapeutics (FDMT) to Market Perform
Jan 10, 2025 08:07AM 4D Molecular Therapeutics (FDMT) Focuses Pipeline to Prioritize 4D-150 in Wet AMD & DME and 4D-710 in CF and Extends Cash Runway
Nov 21, 2024 04:25AM Morgan Stanley Starts 4D Molecular Therapeutics (FDMT) at Underweight
Sep 20, 2024 06:46AM Mizuho Reiterates Outperform Rating on Adverum Biotechnologies (ADVM)
Sep 19, 2024 08:14AM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Sep 19, 2024 08:06AM Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Sep 19, 2024 06:46AM H.C. Wainwright Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Sep 19, 2024 05:25AM Goldman Sachs Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Aug 12, 2024 12:41PM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Aug 9, 2024 06:43AM 4D Molecular Therapeutics, Inc. (FDMT) Tops Q2 EPS by 5c
Jul 22, 2024 06:24AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Jul 18, 2024 08:56AM 4D Molecular Therapeutics (FDMT) PT Lowered to $40 at BMO Capital
Jul 17, 2024 01:19PM 4D Molecular Therapeutics tumbles following mid-stage clinical study results
Jul 17, 2024 01:07PM Chardan Capital Markets Reiterates Buy Rating on 4D Molecular Therapeutics (FDMT)
Jul 9, 2024 07:00PM 2Q24 U.S. biotech earnings preview
Jun 26, 2024 05:40AM RBC Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)
Jun 10, 2024 08:58AM BMO Capital Reiterates Outperform Rating on 4D Molecular Therapeutics (FDMT)